Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aric Parnes

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Blood|November 8, 2019
Clinical utility of targeted next-generation sequencing-based screening of peripheral blood in the evaluation of cytopeniasVignesh Shanmugam, Aric Parnes, Rajeshwari Kalyanaraman, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 22, 2021
Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based systemAric Parnes, Houry Leblebjian, Joanna Hamilton, et al.
British Journal of Haematology|July 19, 2011
Resveratrol ameliorates TNFα-mediated suppression of erythropoiesis in human CD34(+) cells via modulation of NF-κB signallingJee-Yeong Jeong, Matthew Silver, Aric Parnes, et al.
World Journal of Stem Cells|September 14, 2016
Therapy-related myeloid neoplasms - what have we learned so far?Mohammad Faizan Zahid, Aric Parnes, Bipin N Savani, et al.
Blood Reviews|March 21, 2018
Approach to pancytopenia: Diagnostic algorithm for clinical hematologistsJerome Gnanaraj, Aric Parnes, Charles W Francis, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 8, 2021
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studiesAric Parnes, Johnny N Mahlangu, Steven W Pipe, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 28, 2021
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitorsChristine Kempton, Peter Trask, Aric Parnes, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
Origins and diversity of pan-isotype human bone marrow plasma cellsGaspar A Pacheco, Vishal Rao, Duck Kyun Yoo, et al.
Blood|August 12, 2017
Pregnancy outcomes in inherited bone marrow failure syndromesJohn M Gansner, Maureen M Achebe, Kathryn J Gray, et al.
Blood Advances|October 3, 2024
Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohortJacqueline N Poston, Cassandra Bryan, Annette von Drygalski, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Blood|November 8, 2019
Clinical utility of targeted next-generation sequencing-based screening of peripheral blood in the evaluation of cytopeniasVignesh Shanmugam, Aric Parnes, Rajeshwari Kalyanaraman, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 22, 2021
Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based systemAric Parnes, Houry Leblebjian, Joanna Hamilton, et al.
British Journal of Haematology|July 19, 2011
Resveratrol ameliorates TNFα-mediated suppression of erythropoiesis in human CD34(+) cells via modulation of NF-κB signallingJee-Yeong Jeong, Matthew Silver, Aric Parnes, et al.
World Journal of Stem Cells|September 14, 2016
Therapy-related myeloid neoplasms - what have we learned so far?Mohammad Faizan Zahid, Aric Parnes, Bipin N Savani, et al.
Blood Reviews|March 21, 2018
Approach to pancytopenia: Diagnostic algorithm for clinical hematologistsJerome Gnanaraj, Aric Parnes, Charles W Francis, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 8, 2021
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studiesAric Parnes, Johnny N Mahlangu, Steven W Pipe, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 28, 2021
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitorsChristine Kempton, Peter Trask, Aric Parnes, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
Origins and diversity of pan-isotype human bone marrow plasma cellsGaspar A Pacheco, Vishal Rao, Duck Kyun Yoo, et al.
Blood|August 12, 2017
Pregnancy outcomes in inherited bone marrow failure syndromesJohn M Gansner, Maureen M Achebe, Kathryn J Gray, et al.
Blood Advances|October 3, 2024
Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohortJacqueline N Poston, Cassandra Bryan, Annette von Drygalski, et al.
Pageof 2